Swiss pharma company Roche (ROG.SW, RHHBY) is warning that its investment into the US could be at risk due to President Trump's executive order calling for reductions in drug prices. Yahoo Finance senior health reporter Anjalee Khemlani shares more of the details. Catch Bernstein senior analyst Courtney Breen explain to Yahoo Finance why Trump's order is part request and part threat to drugmakers. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Video Transcript 00:00 Speaker A Roche, uh, drug maker, um, that has planned some investment in the US, talking about maybe some risks to that investment. 00:11 Speaker B Yeah, this is based on that executive order that President Trump signed yesterday, looking at the most favored nations, or rather earlier this week, the most favored nations, which is focusing on reducing drug prices. Roche saying in a, uh, a comment to Bloomberg that if the proposed executive order goes into effect, their ability to fund investments that were previously announced, and they are referring to a $50 billion investment in manufacturing, uh, could be put in question. This is the first company to come out kind of against us and we weren't kind of expecting this because the drug companies have made clear, big pharma has made clear that these huge announcements ranging up to 55 billion dollars, that that highest number from J&J, Eli Lilly also with about 50 billion in total. All of these announcements have been geared towards avoiding any other ongoing pressure including this most favored nations clause, including potential additional tariffs. We've also heard from AstraZeneca in a statement to us saying that it would, uh, this most favored nation clause would need a robust, uh, stakeholder investment and inclusion. So really trying to see what the industry does in light of all this additional pressure. Related Videos 01:25 Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill Yahoo Finance Video • 18 minutes ago 01:02 AMD announces $6B share buyback program. Stock gets lift. Yahoo Finance Video • 31 minutes ago 02:22 Markets Lack Significant Positive Change, Citi's Moore Says Bloomberg • 58 minutes ago 06:52 BofA Sees Consumers Still Healthy, But Moderating Bloomberg • 1 hour ago View Comments
Roche warns Trump's drug price order puts US investment at risk
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...